M. Seferoglu Et Al. , "Treatment adherence is more crucial in extended interval dosing than standard dosing among natalizumab users," MULTIPLE SCLEROSIS JOURNAL , pp.975-976, 2023
Seferoglu, M. Et Al. 2023. Treatment adherence is more crucial in extended interval dosing than standard dosing among natalizumab users. MULTIPLE SCLEROSIS JOURNAL , 975-976.
Seferoglu, M., Sivaci, A. O., Cinar, B. P., Tunc, A., BÜNÜL, S. D., Ethemoglu, O., ... Tekan, U. Y.(2023). Treatment adherence is more crucial in extended interval dosing than standard dosing among natalizumab users. MULTIPLE SCLEROSIS JOURNAL , 975-976.
Seferoglu, Meral Et Al. "Treatment adherence is more crucial in extended interval dosing than standard dosing among natalizumab users," MULTIPLE SCLEROSIS JOURNAL , 975-976, 2023
Seferoglu, Meral Et Al. "Treatment adherence is more crucial in extended interval dosing than standard dosing among natalizumab users." MULTIPLE SCLEROSIS JOURNAL , pp.975-976, 2023
Seferoglu, M. Et Al. (2023) . "Treatment adherence is more crucial in extended interval dosing than standard dosing among natalizumab users." MULTIPLE SCLEROSIS JOURNAL , pp.975-976.
@article{article, author={Meral Seferoglu Et Al. }, title={Treatment adherence is more crucial in extended interval dosing than standard dosing among natalizumab users}, journal={MULTIPLE SCLEROSIS JOURNAL}, year=2023, pages={975-976} }